CLAIMS:

1. Use of a compound of formula (I):

(I) 

wherein:

L1 is a direct bond ~~or a linker group selected from O, S, SO_2, NR^7, $C(R^7)_2$ and C=O~~;

R^1 and R^2 are each independently selected from H and optionally substituted C_{1-6} alkyl, C_5-C_{14} aryl, C_5-C_{14} heteroaryl, C_3-C_{14} carbocyclyl and C_3-C_{14} heterocyclyl, the optional substitution being with one or more substituents selected from halo, CN, NO_2, R^6, OR^6, $N(R^6)_2$, COR^6, CO_2R^6, SO_2R^6, NR^7COR^6, $NR^7CO_2R^6$, $NR^7SO_2R^6$, $NR^7CONR^6R^7$, $CONR^6R^7$ and $SO_2NR^6R^7$, provided that at least one of R^1 and R^2 is cyclic;

Each R^5 is independently selected from H, halo, C_{1-6} alkyl, OR^7, $N(R^7)_2$, CN and NO_2;

X^1 ~~and X^2~~-X^4 are each independently selected from N ~~and CR^3~~, NR^4 and NH; and

~~X^3 is selected from NR^4, O and S;~~

~~X^4 is NH; and~~

~~R^3 is selected from H, halo and C_{1-6} alkyl;~~ R^4 is selected from H and C_{1-6} alkyl; R^6 is selected from H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_4-C_7 carbocyclyl, C_4-C_7 heterocyclyl and 5- or 6- membered aryl or heteroaryl, any of which may be optionally substituted with one or more halo atoms; and R^7 is selected from hydrogen and C_1-C_4 alkyl, either of which is optionally substituted with one or more halo atoms;

or a pharmaceutically acceptable N-oxide, salt~~,~~ or hydrate~~, solvate, complex, bioisostere, metabolite or prodrug~~ thereof in the manufacture of a medicament for use in the treatment of infection with *Clostridium difficile* or *Clostridium difficile*-associated disease (CDAD) selected from: (a) colitis; (b) pseudomembranous colitis; and (c) diarrhoea caused by *Clostridium difficile*.

2. The use of claim 1 wherein X^1 and/or X^2 is N.

3. The use of claim 1 or claim 2 wherein X^3 is NR^4.

4. The use of any one of the preceding claims wherein R^1 and R^2 are each independently selected from H and aryl.

5. The use of claim 4 wherein R^1 and R^2 are each independently selected from H and aryl optionally substituted with OR^6 and $N(R^6)_2$.

6. The use of any one of the preceding claims wherein R^1 and R^2 are each cyclic.

7. The use of any one of the preceding claims wherein R^6 is selected from H and C_1-C_6 alkyl.

8. The use of any one of the preceding claims wherein each R^5 is H.

9. The use of any one of the preceding claims wherein L1 is a direct bond~~, for example a direct bond~~ between the 5 and/or 6 positions of each cycle.

10. The use of any one of the preceding claims wherein the compound is symmetrical, for example wherein R^1 and R^2 are the same.

11. The use of any one of claims 1 to 9 wherein the compound is unsymmetrical, for example wherein R^1 and R^2 are different.

12. The use of any one of the preceding claims wherein R^1 and/or R^2 is (are) heterocyclyl or heteroaryl.

13. The use of claim 12 wherein R^1 and/or R^2 is (are): (a) heterocyclyl substituted with one or more substituents selected from halo, CN, NO_2, R^6, OR^6, $N(R^6)_2$, COR^6, CO_2R^6,

SO_2R^6, NR^7COR^6, $NR^7CO_2R^6$, $NR^7SO_2R^6$, $NR^7CONR^6R^7$, $CONR^6R^7$ and $SO_2NR^6R^7$; or (b) heteroaryl substituted with one or more substituents selected from halo, CN, NO_2, R^6, OR^6, $N(R^6)_2$, COR^6, CO_2R^6, SO_2R^6, NR^7COR^6, $NR^7CO_2R^6$, $NR^7SO_2R^6$, $NR^7CONR^6R^7$, $CONR^6R^7$ and $SO_2NR^6R^7$.

14. The use of claim 12 wherein R^1 and/or R^2 is (are) pyridyl.

15. The use of claim 14 wherein R^1 and R^2 are pyridyl.

16. The use of claim 14 or claim 15 wherein the pyridyl is substituted with one or more substituents selected from halo, CN, NO_2, R^6, OR^6, $N(R^6)_2$, COR^6, CO_2R^6, SO_2R^6, NR^7COR^6, $NR^7CO_2R^6$, $NR^7SO_2R^6$, $NR^7CONR^6R^7$, $CONR^6R^7$ and $SO_2NR^6R^7$.

17. The use of claim 15 wherein the compound is 2,2'-Di(pyridin-4-yl)-1H,1'H-5,5'-bibenzo[d]imidazole, or a pharmaceutically acceptable N-oxide, salt~~,~~ or hydrate~~, solvate, complex, bioisostere, metabolite or prodrug~~ thereof.

~~18. The use of any one of the preceding claims wherein the CDAD is selected from: (a) colitis; (b) pseudomembranous colitis; (c) diarrhoea; and (d) antibiotic-associated disease.~~

~~19. The use of claim 18 wherein the antibiotic-associated disease is selected from: (a) antibiotic-associated diarrhoea; and (b) antibiotic-associated colitis.~~

~~20~~18. The use of any one of the preceding claims wherein the compound is a selective *Clostridium difficile* agent.

~~21. The use of claim 20 wherein the compound exhibits: (i) bacteriostatic and/or bacteriocidal activity against one or more strains of *C. difficile* but which does not exhibit bacteriostatic and/or bacteriocidal activity against one or more representative(s) of the normal gut flora selected from: (a) *Escherichia* spp. (for example, *Escherichia coli*); (b) *Bacteroides* spp. (for example, *B. fragilis*); (c) *Fusobacterium* spp.; (d) *Eubacterium* spp. (e) *Ruminococcus* spp. (f) *Peptococcus* spp.; (g) *Peptostreptococcus* spp.; (h) *Bifidobacterium* spp; and (i) *Lactobacillus* spp.; or (ii) bacteriostatic and/or bacteriocidal activity against one or more strains of *C. difficile* but does not exhibit bacteriostatic and/or bacteriocidal activity (MIC >64 µg/mL) against *B. fragilis* ATCC25285; or (iii) bacteriostatic~~

~~and/or bacteriocidal activity against one or more strains of *C. difficile* but does not exhibit bacteriostatic and/or bacteriocidal activity (MIC >64 µg/mL) against both *Bacteroides fragilis* ATCC25285 and *Escherichia coli* ATCC25922; or (iv) no bacteriostatic and/or bacteriocidal activity against normal gut flora to a clinically significant extent.~~

~~22. A combination comprising a compound as defined in any one of the preceding claims and an adjunctive agent selected from: (a) vancomycin; (b) metronidazole; (c) a probiotic; (d) a pre-biotic; (e) a bacteriotoxin sequestrant (e.g. ion exchange resin); (f) intravenous immunoglobulin; and (g) an anti-diarrhoeal agent.~~

~~23~~19. 2,2'-Di(pyridin-4-yl)-1H,1'H-5,5'-bibenzo[d]imidazole, or a pharmaceutical acceptable N-oxide, salt~~,~~ or hydrate~~, solvate, complex, bioisostere, metabolite or prodrug~~ thereof, for use as an antibiotic.

~~24~~20. A pharmaceutical composition comprising 2,2'-Di(pyridin-4-yl)-1H,1'H-5,5'-bibenzo[d]imidazole, or a pharmaceutical acceptable N-oxide, salt~~,~~ or hydrate~~, solvate, complex, bioisostere, metabolite or prodrug~~ thereof.